0
1. 5. 2025.
Su1849: LONG-TERM OUTCOMES OF EXTENDED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVAL FOR PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: 3-YEAR FOLLOW-UP OF THE RANDOMIZED CONTROLLED LADI TRIAL